FTC Complaint Alleges Insulin ‘Middlemen’ Artificially Inflated Prices
Some companies pushed back on the accusations, saying the accusations showed that the government doesn’t understand how drug pricing works. The Federal Trade Commission (FTC) is suing major pharmacy benefit managers (PBMs) for allegedly artificially inflating the price of insulin, the agency said in an announcement on Sept. 20. Three PBMs—CVS Health’s Caremark, Cigna’s Express